Octaplex (Human Coagulation Factor Ix, Protein C, Human Coagulation Factor Vii, Protein S, Human Coagulation F)

The preparation supplies the vitamin K‑dependent clotting factors II, VII, IX, and X together with regulatory proteins C and S. By raising their plasma levels, it re‑initiates the coagulation cascade, generating thrombin and restoring normal clot formation while also helping regulate anticoagulant pathways.

Dosing of Octaplex is individualized. The prescribing clinician determines the amount based on the patient’s INR, the severity of bleeding, body weight, and the specific clinical scenario. No fixed regimen can be stated without a medical order.

Safety data for Octaplex in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To order Octaplex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Octaplex provides a broad spectrum of vitamin K‑dependent factors plus proteins C and S, offering more comprehensive replacement than single‑factor concentrates or vitamin K alone. Compared with recombinant factor VIIa, it restores multiple clotting steps but may carry a higher thrombotic risk, requiring careful patient selection.

Octaplex must be stored refrigerated at 2‑8 °C. Keep the vial in its original container, protect it from light, and avoid freezing or shaking. Prior to use, inspect for particulates and ensure the solution is at room temperature before intravenous administration.

Octaplex is given as an intravenous infusion. The dose is diluted in a compatible solution and infused over a period determined by the prescriber, usually under close monitoring of coagulation parameters and vital signs during and after the injection.

The most serious adverse events include thromboembolic complications such as deep‑vein thrombosis or pulmonary embolism, disseminated intravascular coagulation, severe allergic reactions including anaphylaxis, and, theoretically, transmission of infectious agents from the plasma source.

Octaplex is contraindicated in patients with known hypersensitivity to any of its plasma‑derived components, in those with active, uncontrolled disseminated intravascular coagulation, and in individuals for whom the risk of thrombosis outweighs the clinical benefit, as determined by the treating physician.